Observational study / 2021
A survey found that 76.9% of responding Mohs surgeons recommend nicotinamide for keratinocyte carcinoma prevention.
A survey of 1,500 members of the American College of Mohs Surgeons was conducted to assess demographics, nicotinamide recommendations, and safety perceptions for keratinocyte carcinoma (KC) prevention. Overall, 76.9% of respondents recommended nicotinamide for KC prevention, with 20% recommending it to over 100 patients in the past year, and 45% reporting patient use durations of 2 years or more. While 63.8% had no concerns regarding long-term safety, having safety concerns (OR 0.30, 95% CI 0.13-0.71) or being in practice for over 10 years (OR 0.20, 95% CI 0.05-0.82) was associated with being less likely to recommend it.
Shows an association, not proof of cause and effect.
- Study type
- Cross-sectional survey
- Who was studied
- 1,500 members of the American College of Mohs Surgeons
- What was measured
- Nicotinamide prescribing patterns and safety perceptions for KC prevention
THE PAPER
Nicotinamide for Keratinocyte Carcinoma Chemoprevention: A Nationwide Survey of Mohs Surgeons.
Desai S, Olbricht S, Ruiz ES, Hartman RI. Dermatol Surg, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.